Insights
Thinking on AI in clinical trials, UK biotech operations, regulatory strategy, and building a better clinical delivery model.
AI & Clinical Operations
AI is moving from hype to practical deployment in clinical trials. From adaptive trial design and real-world evidence integration to AI-assisted document production and predictive site selection, sponsors who understand the landscape in 2026 will make better outsourcing and technology decisions. Here is what is real, what is coming, and what to ignore.
Read article →AI in Clinical
Study start-up generates 15–25 regulatory-grade documents before a single patient is screened. Our AI-assisted pipeline reduces this cycle by approximately 40% without compromising GxP compliance or human oversight.
Read article →Inspection Readiness
Your first MHRA GCP inspection is not something you prepare for in the weeks before inspectors arrive. It is something you build into your QMS from day one. Practical guidance on documentation, training, and continuous inspection readiness.
Read article →UK Biotech
UK biotech sponsors are choosing specialist AI-enabled CROs over traditional mega-CROs. Faster timelines, senior-level attention, and 45–55% cost savings without compromising quality or compliance.
Read article →Industry Perspectives
Small specialist CROs are outperforming traditional mega-CROs for early-phase clinical trials. Agility, senior expertise, and AI-enabled operations deliver faster, cheaper, better outcomes for biotech sponsors.
Read article →Regulatory & Compliance
Practical guide to MHRA GCP inspection readiness for UK clinical trial sponsors. Covers documentation, common findings, TMF audit processes, and how to build inspection-ready systems from day one.
Read article →For Sponsors
Choosing the wrong CRO can cost your programme six months and millions. From team bait-and-switch to change-order business models, these are the warning signs that separate genuine partners from expensive problems.
Read article →Study Start-Up
Feasibility is the single most consequential phase of study start-up. Practical guidance on what data actually predicts site performance, how to navigate the UK site landscape, and the common mistakes that delay trials before the first patient is even screened.
Read article →For Sponsors
The CRO you select for early-phase work shapes your programme's trajectory for years. A practical framework covering evaluation criteria, bid defence strategy, contracting essentials, and the red flags that should end the conversation immediately.
Read article →For Sponsors
The number on the CRO proposal is never the number on the final invoice. Where hidden costs hide, how to spot them, and how to structure contracts that keep your trial on budget — from change-order traps to FTE billing games.
Read article →Clinical Operations
Eighty percent of trials miss enrolment targets. Thirty percent of patients drop out. Practical strategies for recruitment feasibility, site-level tactics, digital outreach, retention frameworks, and the metrics that actually matter.
Read article →Clinical Operations
Clinical supply chain failures are a leading cause of trial delays. Practical guidance on IMP manufacturing, cold chain management, demand forecasting, IRT configuration, and the reconciliation failures that trigger inspection findings.
Read article →AI & Data Management
Honest assessment of AI applications in clinical trial data management — proven tools, emerging capabilities, and marketing hype. Includes a comparison table and compliance framework for UK sponsors evaluating AI-enabled CRO partnerships.
Read article →Drug Safety
Pharmacovigilance in Phase I and II trials is unforgiving. SAE reporting timelines, signal detection, DSMB management, and the regulatory requirements UK sponsors cannot afford to get wrong — including a PV readiness checklist for first-in-human studies.
Read article →